Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2008 1
2011 1
2012 2
2013 3
2014 1
2015 2
2018 1
2019 1
2020 3
2021 6
2022 10
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY).
Vernieri F, Iannone LF, Guerzoni S, Russo A, Barbanti P, Sances G, Cevoli S, Rao R, Lovati C, Ambrosini A, Buzzoni C, Battisti F, Vatteone L, King SML, Torelli F. Vernieri F, et al. Among authors: rao r. Neurol Ther. 2024 Apr;13(2):415-435. doi: 10.1007/s40120-024-00582-0. Epub 2024 Feb 8. Neurol Ther. 2024. PMID: 38329615 Free PMC article.
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.
Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, Schiano di Cola F, Ornello R, Cevoli S, Lovati C, Albanese M, Perrotta A, Cetta I, Rossi SS, Taranta V, Filippi M, Geppetti P, Sacco S, Altamura C. Vernieri F, et al. Among authors: rao r. J Neurol. 2023 Nov;270(11):5436-5448. doi: 10.1007/s00415-023-11872-2. Epub 2023 Jul 19. J Neurol. 2023. PMID: 37468621
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d'Onofrio F, d'Onofrio L, Rao R, Messina S, Di Clemente L, Ranieri A, Autunno M, Sette G, Colombo B, Carnevale A, Aguggia M, Tasillo M, Zoroddu F, Frediani F, Filippi M, Tomino C, Proietti S, Bonassi S; FRIEND-Study Group. Barbanti P, et al. Among authors: rao r. J Headache Pain. 2023 Mar 23;24(1):30. doi: 10.1186/s10194-023-01561-w. J Headache Pain. 2023. PMID: 36949388 Free PMC article.
Photophobia and migraine outcome during treatment with galcanezumab.
Schiano di Cola F, Ceccardi G, Bolchini M, Caratozzolo S, Liberini P, Padovani A, Rao R. Schiano di Cola F, et al. Among authors: rao r. Front Neurol. 2023 Jan 18;13:1088036. doi: 10.3389/fneur.2022.1088036. eCollection 2022. Front Neurol. 2023. PMID: 36742057 Free PMC article.
39 results